These aberrations include dysregulation of oncogenes (more specifically, MYC and ERG) and tumor suppressors (including TP53, RB1, and PTEN), highlighting the disrupted balance between pro‐oncogenic and tumor‐suppressive signaling pathways. The gene discussed is ERG; the disease is neoplasm.